Author

Maureen A. Lyons

UPMC Hillman Cancer CenterORCID 0009-0002-9070-9445Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

Brian Robert IsettiD· 2 shared Jason J. LukeiD· 2 shared Katelyn Smith· 2 shared Riyue BaoiD· 2 shared Adam G. ChatoffiD· 1 shared Adrian V. LeeiD· 1 shared Aidan R. ColeiD· 1 shared Amandine AmalriciD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Brian Robert IsettORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 24, 2025

Integrating Artificial Intelligence-Driven Digital Pathology and Genomics to Establish Patient-Derived Organoids as a Novel Alternative Model for Drug Response in Head and Neck Cancer

Rose Doerfler, Jie Chen, Carl Kim…·Riyue Bao

This study establishes patient-derived organoids (PDOs) for HNSCC drug response testing, integrating AI-driven histopathology and multi-omics analysis to create a scalable preclinical model.

3 citations

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCancer Research CommunicationsPeer-reviewedApr 16, 2024

De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression

Naveen Kumar Tangudu, Raquel Buj, Hui Wang…·Katherine M. Aird

This study identifies de novo purine metabolism as a vulnerability in cancers with low p16 expression, showing sensitivity to anti-folate drugs like methotrexate.

14 citations

humanmouse

𝕏 PostBluesky

Cell BiologyJournal for ImmunoTherapy of CancerPeer-reviewedOct 1, 2023

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma

Ryan C. Augustin, Sarah Newman, Aofei Li…·Riyue Bao

This study identifies 11 oncogenic pathways associated with immune exclusion and ICI resistance in acral melanoma, suggesting therapeutic targets for immunotherapy combinations.

28 citations

humanbulk RNA-seq

𝕏 PostBluesky